Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Rubin

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
Journal of Hepatology|November 30, 2014
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart diseaseMariana Lazo, Jonathan Rubin, Jeanne M Clark, et al.
CNS Drugs|August 13, 2025
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension TrialRobert L Findling, Alain Katic, Michael Liebowitz, et al.
Clinical Biochemistry|March 16, 2016
Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general populationJonathan Rubin, Kunihiro Matsushita, Mariana Lazo, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Annals of Surgical Oncology|February 3, 2025
Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer TreatmentJanet C Coleman-Belin, Jonathan Rubin, Lillian A Boe, et al.
Circulation|August 24, 2014
Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damageElizabeth Selvin, Mariana Lazo, Yuan Chen, et al.
Annals of Surgical Oncology|October 8, 2025
ASO Visual Abstract: Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression TherapyBenjamin D Wagner, Jonathan Rubin, Lillian A Boe, et al.
Blood Purification|February 10, 2015
Quantitative lung ultrasound comet measurement: method and initial clinical resultsWilliam F Weitzel, James Hamilton, Xianglong Wang, et al.
Annals of Surgical Oncology|September 18, 2025
Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression TherapyBenjamin D Wagner, Jonathan Rubin, Lillian A Boe, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Journal of Hepatology|November 30, 2014
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart diseaseMariana Lazo, Jonathan Rubin, Jeanne M Clark, et al.
CNS Drugs|August 13, 2025
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension TrialRobert L Findling, Alain Katic, Michael Liebowitz, et al.
Clinical Biochemistry|March 16, 2016
Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general populationJonathan Rubin, Kunihiro Matsushita, Mariana Lazo, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Annals of Surgical Oncology|February 3, 2025
Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer TreatmentJanet C Coleman-Belin, Jonathan Rubin, Lillian A Boe, et al.
Circulation|August 24, 2014
Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damageElizabeth Selvin, Mariana Lazo, Yuan Chen, et al.
Annals of Surgical Oncology|October 8, 2025
ASO Visual Abstract: Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression TherapyBenjamin D Wagner, Jonathan Rubin, Lillian A Boe, et al.
Blood Purification|February 10, 2015
Quantitative lung ultrasound comet measurement: method and initial clinical resultsWilliam F Weitzel, James Hamilton, Xianglong Wang, et al.
Annals of Surgical Oncology|September 18, 2025
Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression TherapyBenjamin D Wagner, Jonathan Rubin, Lillian A Boe, et al.
Pageof 13